Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
|Study Number||Lead Group||Study Title||CIRB||Study Status|
|8329||ETCTN||A Phase I/II Trial of ABT-888, an Inhibitor of Poly(ADP-ribose) Polymerase (PARP), and Topotecan (TPT) in Patients with Solid Tumors (Phase I) and Relapsed Ovarian Cancer or Primary Peritoneal Cancer (Phase II) After Prior Platinum Containing First-Line Chemotherapy||Adult CIRB - Early Phase Emphasis||Available to Open|
|7977||ETCTN||A Phase I Dose-Escalation Study of Oral ABT-888 (NSC #737664) Plus Intravenous Irinotecan (CPT-11, NSC#616348) Administered in Patients with Advanced Solid Tumors||Adult CIRB - Early Phase Emphasis||Available to Open|
|10292||ETCTN||DURVA+ : Evaluation of the Safety and Pharmacodynamics of Anti-PD-L1 Antibody MEDI4736 (durvalumab) in Combination with Chemotherapy in Patients with Advanced Solid Tumors||Adult CIRB - Early Phase Emphasis||Available to Open|
|10250||ETCTN||A Phase II Study of the PARP Inhibitor Olaparib in Combination with the DNA Damaging Agent Temozolomide for the Treatment of Advanced Uterine Leiomyosarcoma||Adult CIRB - Early Phase Emphasis||Available to Open|
|10249||ETCTN||MLN9708 (Ixazomib) and MLN4924 (Pevonedistat) in Relapsed/Refractory Multiple Myeloma Patients: A Phase 1b Trial||Adult CIRB - Early Phase Emphasis||Available to Open|
|10247||ETCTN||A Randomized Phase II Trial of MLN4924 (Pevonedistat) with Azacitidine versus Azacitidine in Adult Relapsed or Refractory Acute Myeloid Leukemia||Adult CIRB - Early Phase Emphasis||Available to Open|
|10246||ETCTN||A Phase 1 Study of MLN4924 (pevonedistat) and Belinostat in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome||Adult CIRB - Early Phase Emphasis||Available to Open|
|10240||ETCTN||Phase II Study of XL184 (cabozantinib) in combination with Nivolumab and Ipilimumab (CaboNivoIpi) in Patients with Radioiodine-refractory Differentiated Thyroid Cancer whose Cancer Progressed after One Prior VEGFR-Targeted Therapy||Adult CIRB - Early Phase Emphasis||Available to Open|
|10231||NCI||NCORP Tissue Procurement Protocol: An NCI Cancer Moonshot Study||Adult CIRB - Late Phase Emphasis||Available to Open|
|10222||ETCTN||A Phase II study of olaparib and AZD6738 in isocitrate dehydrogenase (IDH) mutant solid tumors||Adult CIRB - Early Phase Emphasis||Available to Open|